Teligent (NASDAQ:TLGT) and Capstone Therapeutics (OTCMKTS:CAPS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
Analyst Ratings
This is a summary of recent ratings for Teligent and Capstone Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Teligent | 0 | 1 | 0 | 0 | 2.00 |
Capstone Therapeutics | 0 | 0 | 0 | 0 | N/A |
Teligent currently has a consensus price target of $2.00, suggesting a potential upside of 284.84%. Given Teligent's higher possible upside, equities analysts clearly believe Teligent is more favorable than Capstone Therapeutics.
Insider & Institutional Ownership
28.2% of Teligent shares are owned by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are owned by institutional investors. 2.1% of Teligent shares are owned by insiders. Comparatively, 42.8% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Teligent and Capstone Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Teligent | -91.50% | N/A | -17.52% |
Capstone Therapeutics | N/A | N/A | N/A |
Volatility & Risk
Teligent has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of 176.15, suggesting that its stock price is 17,515% more volatile than the S&P 500.
Earnings and Valuation
This table compares Teligent and Capstone Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Teligent | $65.90 million | 0.17 | $-25,120,000.00 | N/A | N/A |
Capstone Therapeutics | $2 million | 1.42 | $-380,000.00 | N/A | N/A |
Capstone Therapeutics has lower revenue, but higher earnings than Teligent.
Summary
Capstone Therapeutics beats Teligent on 6 of the 9 factors compared between the two stocks.